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Background. The endothelium can regulate vascular tone by releasing both endothelium-derived relaxing factor (EDRF or nitric oxide) and contracting factors. To date, there has only been circumstantial evidence to indicate EDRF activity in vivo in human coronary arteries. Using human hemoglobin as a specific inhibitor, the hypothesis that acetylcholine-induced coronary vasodilation is due to EDRF release was tested.
Methods and Results. We studied the response of normal coronary arteries to acetylcholine (an endothelium-dependent vasodilator) and isosorbide dinitrate (an endothelium-independent vasodilator) in seven patients. The specificity of any vasodilator response was assessed by the infusion of reduced free human hemoglobin. Hemoglobin 10-M infusion alone had no effect on coronary artery diameter. Drugs were infused into the coronary artery, and the diameter changes were assessed by quantitative angiography. Acetylcholine 10-M increased left anterior descending coronary artery diameter from control: 230±0.12 mm to 2.79±0.20 mm (mean+SEM, n=7, p<0.01). Hemoglobin both in a concentration of 10`M and 10`M reversed this vasodilator effect, causing constriction to 2.11±0.18 mm (p<0.001 compared with acetylcholine 10-M) and 2.29±0.14 mm (p<0.05 compared with acetylcholine 10-M).
Isosorbide dinitrate in the presence of hemoglobin caused dilatation of the coronary artery in all cases to 3.04±0.24 mm (p<0.001 compared with acetylcholine 10`M and hemoglobin 10-6 M).
Conclusions. Using a specific inhibitor of nitric oxide, reduced free hemoglobin, we have demonstrated that basal EDRF release does not appear to play an important role in the maintenance of human epicardial coronary artery diameter in vivo but is responsible for the acetylcholine-induced dilatation. (Circulation 1993;87:80-85) KEY To rule out the possibility of tachyphylaxis to acetylcholine, six patients were given intracoronary control infusion followed by acetylcholine 10-' M, and angiograms were performed at 3 and 9 minutes after the start of the acetylcholine infusion.
Human and Rabbit Coronary Artery In Vitro Study Protocol
Parallel studies were conducted in vitro using human and rabbit coronary arteries to test the agents used in Proximal left anterior descending coronary arteries were excised from male New Zealand White rabbits (weight, 2-3 kg) and from coronary vessels from normal human donor hearts obtained from the transplant program at the Royal Brompton National Heart and Lung Hospitals. The vessels were trimmed of adhering fat and connective tissue as previously described.21 Transverse rings of coronary artery were cut with surgical blades. In some of the rings, endothelium was removed by gentle rubbing. The rings were mounted in glass 10-ml organ baths at 37°C. The bathing fluid was Krebs solution containing (mM): NaCI 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 24, glucose 11, and Na2 EDTA 0.03. It was continuously gassed with 95% 02-5% CO2. Two stainless steel hooks were used to mount each ring. The lower hook was attached to the base of the muscle chamber, the upper to a strain gauge. All preparations were equilibrated for 90 minutes, and basal tension was set to 1 g before drug additions. The records show the point at which the drug addition was made.
Quantitative Coronary Angiography
Selective left coronary arteriography was performed by the injection of 7-8 ml of nonionic, low-osmolar radiographic contrast medium (iohexol) containing 350 mg of iodine per milliliter at a rate of 5 Calibration and end-diastolic cineframes were then videodigitized using an IGE CAP35 cineprojector and Kontron Cardio 500 Image processing workstation. Each frame was stored on a 5122-pixel matrix with digitization to a depth of eight bits with a resultant 256 shades of gray per pixel. The calibration images for each patient were analyzed to correct for geometric magnification and to determine the distance in millimeters for each pixel. This ranged from 0.15 to 0.20 mm/pixel, (mean, 0.18). Calibration and diameter measurements of the coronary artery segments were performed using the interactive program of the micro Mipron interpreter software installed on the Cardio 500 workstation.
Both the calibration and vessel diameter measurements were performed by an independent observer who was unaware of the infusion sequence or protocol.
Drugs
Human hemoglobin from donors negative for hepatitis B surface antigen and human immunodeficiency viral antibodies 1 and 2 tested for by enzyme-linked immunosorbant assay was supplied by Sigma Chemical Company. It contained a mixture of oxyhemoglobin and methemoglobin and was prepared as previously described.'8 The following procedures were performed in the department of hematology. A 20-mM excess of reducing agent, sodium dithionite (Na2S204), was added to a 1-mM solution of twice-crystallized human hemoglobin. Sodium dithionite was removed by dialysis usingsis and always contained less than 5% methemoglobin. Sterility during the procedure was assured by the use of sterile, pyrogen-free water and containers. These were deoxygenated by gassing with oxygen-free nitrogen. The final solution was filtered through 0.45-and 0.2-,um filters (Flow Laboratories) and filtered again immediately before use in the patients. The solutions were stored at -800C for no longer than 2 weeks. Samples of the solutions used in the patients were immediately subjected to repeat electrophoresis (for methemoglobin), and these solutions always contained less than 5% methemoglobin. The solutions were assessed for pyrogens using rabbit pyrogen 10`M and hemoglobin 10`6 M). Hemoglobin (10-5 M) alone had no effect on coronary artery diameter ( Figure  1) . No evidence for tachyphylaxis to acetylcholine infusion was found. Acetylcholine 10`M significantly increased coronary artery diameter from control: 2.35±0.11 mm to 2.97±0.11 at 3 minutes and 2.90±0.17 at 9 minutes from the start of the infusion (p=NS between 3 and 9 minutes of acetylcholine 10-7 M; p<0.01 and 0.05 compared with control and acetylcholine 10-7 M at 3 and 9 minutes, respectively).
Heart rate, systemic arterial pressure, and ECG did not change in any patient. There were no reported sensations, and none of the subjects was aware of the infusions. Hemoglobin, white cell count, platelet count, urea and electrolytes, prothrombin time, kaolin, and cephalin clotting time were no different after the study.
In Vitro Study
Acetylcholine 10-7 M relaxed KCI-preconstricted human epicardial coronary arteries by 56±-6% (n=4, Acetylcholine has been identified as a coronary vasodilator in patients with angiographically normal coronary arteries. 10, 1122 The specificity of this vasodilation has not been fully tested. Indeed, some authors claim that acetylcholine causes epicardial coronary artery constriction.2324 However, the doses of acetylcholine in one study were higher23 than used previously'0 and in this study. Other workers have used bolus injections' 122 that do not achieve steady-state drug concentration in the coronary artery. Also, it has recently been claimed that risk factors for coronary artery disease positively correlate with an abnormal vasoconstrictor response to acetylcholine in angiographically normal coronary arteries. 25 We confirm that at a concentration of 10`M, acetylcholine significantly increased epicardial coronary diameter.
The concept of using hemoglobin solutions as blood substitutes has been recognized for many found that the toxicity was due to red cell stromal contamination.26 Removal of the stromal element has largely eliminated the potential renal toxicity.26'27 Clinical safety trials of stroma-free hemoglobin have been performed in which 250 ml of hemoglobin solution (equivalent to 16 g of hemoglobin) was infused into each of eight healthy men. 28 Gross hemoglobinuria appeared, as expected, during the stroma-free hemoglobin infusion and completely disappeared by 6-10 hours after infusion. Cardiovascular, renal, and clotting changes were present for only a few hours after the stroma-free hemoglobin infusion. At 24 hours and 7 days after infusion, all measurements were normal, and 6-month follow-up showed no abnormalities or hepatitis. In our study, a total of 1.5 mg of hemoglobin was locally infused into the coronary circulation. This is over 10,000 times less than has been safely infused into healthy volunteers, and, as expected, there was no evidence of renal or clotting abnormalities detected after the study.
Hemoglobin binds avidly to nitric oxide.19 Hemoglobin may be combining with nitric oxide at the luminal endothelial cell surface, and this may create a "sink" for intimally released nitric oxide. An alternative explanation is that hemoglobin is penetrating the endothelial cell surface either by endocytosis or transcytosis. Immonocytochemical procedures have been used to localize albumin transport through the capillary endothelium of the murine myocardium.29 It appears to pass through the endothelium via plasmalemmal vesicles and appears in the pericapillary spaces less than 15 seconds after the beginning of its perfusion. Albumin has a molecular weight of approximately 69,000 and tetrameric hemoglobin a molecular weight of approximately 64,000. Both are globular proteins and have similar molecular radii. The possibility exists that tetrameric hemoglobin may follow a similar transcytotic vesicular pathway through the coronary vascular endothelium in vivo. 30 Although the hemoglobin used in this study was shown electrophoretically to be the tetrameric form, there is evidence in vivo that the tetramer, composed of two polypeptide chains, dissociates into two peptide chain dimers,31 which would, theoretically, enable an even faster endothelial transit time. This, of course, cannot be shown to be the case in this study. It is also noteworthy that the permeability of the renal glomeruli for hemoglobin is even greater than that for albumin and molecules of similar molecular weight.32 Hemoglobin may therefore follow a similar pathway and would then be available at an appropriate site to inhibit released nitric oxide in the subendothelial space. Myoglobin (molecular weight, 17,800) has been shown to penetrate the endothelium within 30 seconds. 33 Hemoglobin solutions have been demonstrated to have coronary vasoconstrictor activity in the isolated, buffer-perfused rabbit heart.34 This vasoconstrictor activity was considerably reduced by the purification of the hemoglobin. It is reassuring that in our study, when hemoglobin alone was infused, it did not appear to have a direct vasoconstrictor effect. However, it did abolish the acetylcholine-induced endothelium-dependent vasodilation. This would argue against an important basal EDRF effect in the epicardial coronary arteries in humans and also against a direct vasoconstrictor effect of the reduced hemoglobin used in our study. A coronary vasoconstrictor effect of human stroma-free hemoglobin has been identified in isolated rabbit hearts perfused with Krebs-Henseleit solution.35 More importantly, in this study, the vasoconstrictor effect was preserved when the rabbit heart was perfused with whole blood at a constant coronary flow rate. In bufferperfused hearts, stroma-free hemoglobin in concentrations of 5-200 mg/dl produced dose-related increases of coronary perfusion pressure. In blood-perfused hearts, increasing plasma hemoglobin to 1.6±0.1 g/dl (2.5 x 10-4 M) without changing total hemoglobin or arterial oxygen content increased coronary perfusion pressure by 36±13 mm Hg. It was concluded from this study that stroma-free hemoglobin solutions exert a coronary vasoconstrictor effect that is unrelated to oxygen delivery and may involve the inhibition of some tonic dilator activity (e.g., EDRF-nitric oxide). There is evidence that hemoglobin possesses direct smooth muscle constrictor activity in isolated cerebral arteries from certain species36,37 and that it may release a vasoconstrictor prostaglandin in monkey and dog cerebral arteries38 and pig coronary arteries.39 There was no evidence that the reduced free human hemoglobin used in this study had any direct constrictor activity in human or rabbit coronary arteries either in vitro or in vivo.
Increasing blood flow has been shown to result in endothelium-dependent relaxation of animal epicardial coronary arteries. 40, 41 There are studies that suggest that this mechanism exists in angiographically normal coronary arteries in humans42-44 by demonstration of proximal increases in coronary artery diameter to the pharmacological agents papaverine,42 adenosine,43 and acetylcholine.44 Flow-induced dilation was shown to be defective in patients with coronary artery irregularities as a result of coronary atherosclerosis.4344 Coronary vascular resistance was not measured in this study. It is therefore theoretically possible that the epicardial coronary artery diameter increases are due to a flowmediated effect of acetylcholine by a decrease in coronary vascular resistance (microvascular endothelial EDRF release), resulting in the release of EDRF from the epicardial coronary artery endothelium. If the mechanism of acetylcholine-induced increase in epicardial coronary artery diameter is flow-mediated, it still does not detract from the fact that this acetylcholineinduced (presumed to be due to nitric oxide released from the endothelium) epicardial coronary artery dilator effect has been reversed by an infusion of hemoglobin, thus implying that at whatever level (epicardial or microvascular) nitric oxide release is being stimulated by acetylcholine, its effect is being reversed by the infused hemoglobin.
Direct evidence that endothelium-dependent dilation is present in humans in vivo was first shown in the large dorsal veins of the hands of normal subjects.45 Subsequently, specific inhibition of endothelium-derived nitric oxide has been achieved in the forearm of healthy human volunteers. 16 Infusion of NG-monomethyl-L-arginine attenuated the increase in flow induced by acetylcholine, and the effect of N0-monomethyl-L-arginine could be partly reversed by L-arginine. NG-monomethyl-L-arginine appears to cause substantial vasoconstriction that can last for 45-60 minutes unless L-arginine is used partially to reverse the effect. Such a long-lasting effect could theoretically be dangerous in the coronary vascular bed. Reduced hemoglobin appears to have a short-acting, easily reversible effect.
This study provides strong evidence that basal nitric oxide release does not play an important role in the maintenance of epicardial coronary artery diameter in vivo. This, of course, does not rule out an important role for basal nitric oxide in the microvascular coronary bed. It also strongly suggests that endothelium-derived nitric oxide is responsible for the acetylcholine-induced dilation in human coronary arteries in vivo. Reduced free hemoglobin appears to be an effective inhibitor of endothelium-derived nitric oxide in vivo and has been shown to be safe at the concentrations used in these studies.
